What do systematic reviews say?

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis

QoL · adults aged over 50 years with giant cell arteritis

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Adverse events · adults with asthma

Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease

Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease

Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease

Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease